Clinical features of patients in group 1 and group 2 and their PICP and PIIINP concentrations in CSF and serum
| Patient group | ||||
|---|---|---|---|---|
| Group 1 controls Mean (SD) | Group 1 patients Mean (SD) | Group 2 patients Mean (SD) | Range | |
| Clinical description | No CNS disease | Neurological disease with abnormal CSF | Recent SAH | |
| Men/women (n) | 9/12 | 7/4 | 5/4 | |
| Age (y) | 40.9 (14.4) | 44.3 (13.0) | 46.4 (9.1) | |
| CSF leucocytes (×109/l) | 1; range 0–3 | 1; range 0–50 | ND | |
| CSF protein (mg/l) | 320 (115) | 741 (397)† | 995 (514)¶ | 377–1974 |
| PICP | ||||
| In CSF (μg/l) | 75.2 (13.6) | 103 (19.2)‡ | 447 (222)¶ | 175–898 |
| In serum (μg/l) | 110 (37.3) | 126 (35.0) | 77.7 (33.9)2-150 | 43.9–144 |
| CSF/serum ratio | 0.74 (0.23) | 0.84 (0.25) | 5.96 (3.72)¶ | 1.41–13.9 |
| PIIINP | ||||
| In CSF (μg/l) | 3.56 (0.91) | 5.14 (1.65)‡ | 27.5 (20.8)¶ | 11.1–74.6 |
| In serum (μg/l) | 2.85 (0.78) | 3.41 (1.23) | 2.22 (1.40) | 1.05–5.52 |
| CSF/serum ratio | 1.34 (0.48) | 1.70 (1.11) | 15.2 (12.1)¶ | 3.87–42.3 |
| PICP/PIIINP ratio | ||||
| In CSF | 21.7 (3.11) | 20.9 (4.11) | 18.5 (6.21) | 12.0–29.7 |
| In serum | 42.2 (20.3) | 41.6 (18.8) | 39.1 (11.7) | 22.2–57.9 |
↵2-150 p<0.05; †p<0.01; ‡p=0.001; ¶p<0.001; ND=not determined.